Swiss National Bank Recursion Pharmaceuticals, Inc. Transaction History

Swiss National Bank

$150 Billion
Q3 2024

A detailed history of Swiss National Bank transactions in Recursion Pharmaceuticals, Inc. stock. As of the latest transaction made, Swiss National Bank holds 357,100 shares of RXRX stock, worth $2.59 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

357,100

Previous 355,200 0.53%

Holding current value

$2.59 Million

Previous $2.66 Million 11.67%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 07, 2024	BUY	$5.92 - $8.6 $11,248 - $16,340	1,900 Added 0.53%	357,100 $2.35 Million
Q2 2024 Aug 08, 2024	BUY	$7.35 - $10.05 $343,245 - $469,335	46,700 Added 15.14%	355,200 $2.66 Million
Q1 2024 May 07, 2024	BUY	$9.13 - $15.52 $247,423 - $420,592	27,100 Added 9.63%	308,500 $3.08 Million
Q4 2023 Feb 06, 2024	SELL	$5.09 - $10.79 $13,743 - $29,132	-2,700 Reduced 0.95%	281,400 $2.77 Million
Q3 2023 Nov 08, 2023	BUY	$6.59 - $15.86 $30,314 - $72,956	4,600 Added 1.65%	284,100 $2.17 Million
Q2 2023 Aug 09, 2023	BUY	$4.56 - $9.94 $738,263 - $1.61 Million	161,900 Added 137.67%	279,500 $2.09 Million
Q1 2023 May 10, 2023	SELL	$6.42 - $9.64 $12,840 - $19,280	-2,000 Reduced 1.67%	117,600 $784,000
Q4 2022 Feb 08, 2023	BUY	$7.16 - $12.7 $22,196 - $39,370	3,100 Added 2.66%	119,600 $922,000
Q3 2022 Nov 09, 2022	BUY	$7.83 - $13.6 $28,971 - $50,320	3,700 Added 3.28%	116,500 $1.24 Million
Q2 2022 Aug 09, 2022	BUY	$5.04 - $9.26 $93,240 - $171,310	18,500 Added 19.62%	112,800 $918,000
Q1 2022 May 09, 2022	BUY	$6.16 - $18.03 $41,272 - $120,801	6,700 Added 7.65%	94,300 $675,000
Q4 2021 Feb 08, 2022	BUY	$16.14 - $21.86 $1.41 Million - $1.91 Million	87,600 New	87,600 $1.5 Million

Others Institutions Holding RXRX

# of Institutions

286

Shares Held

242M

Call Options Held

1.35M

Put Options Held

2.32M

View Full List

About RECURSION PHARMACEUTICALS, INC.

Ticker RXRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 180,480,000
Market Cap $1.31B
Description
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cav...

More about RXRX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Swiss National Bank, based on Form 13F filings with the SEC.

News

Stay updated on Swiss National Bank with notifications on news.

Account

Swiss National Bank Recursion Pharmaceuticals, Inc. Transaction History